Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
1779 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Melanoma - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Melanoma - Pipeline Review, H1 2017, provides an overview of the Melanoma (Oncology) pipeline landscape. Melanoma is a tumor that develops as a result of the malignant transformation of melanocytes. These cells are derived from the neural crest. Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. In women, the most common site is the legs and melanomas in men are most common on the back. Unusual moles, sores, lumps, blemishes, markings, or changes in the way an area of the skin looks or feels are sign of melanoma. Treatment includes surgery, radiation and proton therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Melanoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 20, 105, 120, 7, 214, 29 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 14, 13, 1, 62 and 14 molecules, respectively. Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Melanoma (Oncology). - The pipeline guide reviews pipeline therapeutics for Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Melanoma (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Melanoma (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Melanoma (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Melanoma (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 11 Melanoma - Overview 12 Melanoma - Therapeutics Development 13 Melanoma - Therapeutics Assessment 71 Melanoma - Companies Involved in Therapeutics Development 103 Melanoma - Drug Profiles 230 Melanoma - Dormant Projects 1675 Melanoma - Discontinued Products 1701 Melanoma - Product Development Milestones 1705 Appendix 1721
List of Tables
Number of Products under Development for Melanoma, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..12), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..13), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..14), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..15), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..16), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..4), H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Companies, H1 2017 (Contd..4), H1 2017 Products under Development by Companies, H1 2017 (Contd..5), H1 2017 Products under Development by Companies, H1 2017 (Contd..6), H1 2017 Products under Development by Companies, H1 2017 (Contd..7), H1 2017 Products under Development by Companies, H1 2017 (Contd..8), H1 2017 Products under Development by Companies, H1 2017 (Contd..9), H1 2017 Products under Development by Companies, H1 2017 (Contd..10), H1 2017 Products under Development by Companies, H1 2017 (Contd..11), H1 2017 Products under Development by Companies, H1 2017 (Contd..12), H1 2017 Products under Development by Companies, H1 2017 (Contd..13), H1 2017 Products under Development by Companies, H1 2017 (Contd..14), H1 2017 Products under Development by Companies, H1 2017 (Contd..15), H1 2017 Products under Development by Companies, H1 2017 (Contd..16), H1 2017 Products under Development by Companies, H1 2017 (Contd..17), H1 2017 Products under Development by Companies, H1 2017 (Contd..18), H1 2017 Products under Development by Companies, H1 2017 (Contd..19), H1 2017 Products under Development by Companies, H1 2017 (Contd..20), H1 2017 Products under Development by Companies, H1 2017 (Contd..21), H1 2017 Products under Development by Companies, H1 2017 (Contd..22), H1 2017 Products under Development by Companies, H1 2017 (Contd..23), H1 2017 Products under Development by Companies, H1 2017 (Contd..24), H1 2017 Products under Development by Companies, H1 2017 (Contd..25), H1 2017 Products under Development by Companies, H1 2017 (Contd..26), H1 2017 Products under Development by Universities/Institutes, H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..4), H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..5), H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..8), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..9), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..10), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..11), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..12), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..9), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..10), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..11), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 (Contd..1), H1 2017 Melanoma - Pipeline by 4P-Pharma SAS, H1 2017 Melanoma - Pipeline by 4SC AG, H1 2017 Melanoma - Pipeline by AB Science SA, H1 2017 Melanoma - Pipeline by AbbVie Inc, H1 2017 Melanoma - Pipeline by Abivax SA, H1 2017 Melanoma - Pipeline by Adaptimmune Therapeutics Plc, H1 2017 Melanoma - Pipeline by Aduro BioTech Inc, H1 2017 Melanoma - Pipeline by Advanced Cancer Therapeutics LLC, H1 2017 Melanoma - Pipeline by Affichem SA, H1 2017 Melanoma - Pipeline by Agenus Inc, H1 2017 Melanoma - Pipeline by AGV Discovery SAS, H1 2017 Melanoma - Pipeline by AIMM Therapeutics BV, H1 2017 Melanoma - Pipeline by Alethia Biotherapeutics Inc, H1 2017 Melanoma - Pipeline by Alkermes Plc, H1 2017 Melanoma - Pipeline by Altor BioScience Corp, H1 2017 Melanoma - Pipeline by Amgen Inc, H1 2017 Melanoma - Pipeline by Anavex Life Sciences Corp, H1 2017 Melanoma - Pipeline by Angimmune LLC, H1 2017 Melanoma - Pipeline by Antibe Therapeutics Inc, H1 2017 Melanoma - Pipeline by Antigen Express Inc, H1 2017 Melanoma - Pipeline by APEIRON Biologics AG, H1 2017 Melanoma - Pipeline by Apexigen Inc, H1 2017 Melanoma - Pipeline by Aphios Corp, H1 2017 Melanoma - Pipeline by Apogenix GmbH, H1 2017 Melanoma - Pipeline by Aposense Ltd, H1 2017 Melanoma - Pipeline by Aptose Biosciences Inc, H1 2017 Melanoma - Pipeline by ARMO Biosciences Inc, H1 2017 Melanoma - Pipeline by Array BioPharma Inc, H1 2017 Melanoma - Pipeline by Asana BioSciences LLC, H1 2017 Melanoma - Pipeline by Astellas Pharma Inc, H1 2017 Melanoma - Pipeline by Astex Pharmaceuticals Inc, H1 2017 Melanoma - Pipeline by AstraZeneca Plc, H1 2017 Melanoma - Pipeline by Aurigene Discovery Technologies Ltd, H1 2017 Melanoma - Pipeline by Autotelic Inc, H1 2017 Melanoma - Pipeline by Basilea Pharmaceutica Ltd, H1 2017 Melanoma - Pipeline by Batu Biologics Inc, H1 2017 Melanoma - Pipeline by Bayer AG, H1 2017 Melanoma - Pipeline by BeiGene (Beijing) Co Ltd, H1 2017 Melanoma - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H1 2017 Melanoma - Pipeline by Bellicum Pharmaceuticals Inc, H1 2017 Melanoma - Pipeline by BerGenBio ASA, H1 2017 Melanoma - Pipeline by Bio-Cancer Treatment International Ltd, H1 2017 Melanoma - Pipeline by Biocad, H1 2017 Melanoma - Pipeline by Biogazelle NV, H1 2017 Melanoma - Pipeline by BioLineRx Ltd, H1 2017 Melanoma - Pipeline by Bioncotech Therapeutics SL, H1 2017 Melanoma - Pipeline by Bionomics Ltd, H1 2017 Melanoma - Pipeline by BioNTech AG, H1 2017 Melanoma - Pipeline by Biothera Pharmaceutical Inc, H1 2017 Melanoma - Pipeline by Biovista Inc, H1 2017 Melanoma - Pipeline by Boehringer Ingelheim GmbH, H1 2017 Melanoma - Pipeline by Boston Biomedical Inc, H1 2017 Melanoma - Pipeline by Bristol-Myers Squibb Company, H1 2017 Melanoma - Pipeline by Calithera Biosciences Inc, H1 2017 Melanoma - Pipeline by Can-Fite BioPharma Ltd, H1 2017 Melanoma - Pipeline by CCRP Therapeutics GmbH, H1 2017 Melanoma - Pipeline by Celgene Corp, H1 2017 Melanoma - Pipeline by Celldex Therapeutics Inc, H1 2017 Melanoma - Pipeline by Celprogen Inc, H1 2017 Melanoma - Pipeline by Celyad SA, H1 2017 Melanoma - Pipeline by Checkmate Pharmaceuticals Inc, H1 2017 Melanoma - Pipeline by Chipscreen Biosciences Ltd, H1 2017 Melanoma - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017 Melanoma - Pipeline by Cipher Pharmaceuticals Inc, H1 2017 Melanoma - Pipeline by Corvus Pharmaceuticals Inc, H1 2017 Melanoma - Pipeline by CytomX Therapeutics Inc, H1 2017 Melanoma - Pipeline by Cytori Therapeutics Inc, H1 2017 Melanoma - Pipeline by Cytune Pharma SAS, H1 2017 Melanoma - Pipeline by CyTuVax BV, H1 2017 Melanoma - Pipeline by CZ BioMed Corp, H1 2017 Melanoma - Pipeline by Daiichi Sankyo Company Ltd, H1 2017 Melanoma - Pipeline by Deciphera Pharmaceuticals LLC, H1 2017 Melanoma - Pipeline by DEKK-TEC Inc, H1 2017 Melanoma - Pipeline by Dicerna Pharmaceuticals Inc, H1 2017 Melanoma - Pipeline by Dynavax Technologies Corp, H1 2017 Melanoma - Pipeline by Eisai Co Ltd, H1 2017 Melanoma - Pipeline by Eli Lilly and Company, H1 2017 Melanoma - Pipeline by Elsalys Biotech SAS, H1 2017 Melanoma - Pipeline by Ensol Biosciences Inc, H1 2017 Melanoma - Pipeline by EntreChem SL, H1 2017 Melanoma - Pipeline by eTheRNA Immunotherapies NV, H1 2017 Melanoma - Pipeline by Exelixis Inc, H1 2017 Melanoma - Pipeline by Exicure Inc, H1 2017 Melanoma - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 Melanoma - Pipeline by Faron Pharmaceuticals Oy, H1 2017 Melanoma - Pipeline by Galapagos NV, H1 2017 Melanoma - Pipeline by Galectin Therapeutics Inc, H1 2017 Melanoma - Pipeline by Genelux Corp, H1 2017 Melanoma - Pipeline by Genocea Biosciences Inc, H1 2017 Melanoma - Pipeline by Genzyme Corp, H1 2017 Melanoma - Pipeline by GlaxoSmithKline Plc, H1 2017 Melanoma - Pipeline by Gradalis Inc, H1 2017 Melanoma - Pipeline by GreenPeptide Co Ltd, H1 2017 Melanoma - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2017 Melanoma - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017 Melanoma - Pipeline by Heat Biologics Inc, H1 2017 Melanoma - Pipeline by Hemispherx Biopharma Inc, H1 2017 Melanoma - Pipeline by Histogen Inc, H1 2017 Melanoma - Pipeline by HitGen LTD, H1 2017 Melanoma - Pipeline by Horizon Pharma Plc, H1 2017 Melanoma - Pipeline by Humorigin Biotechnology Corp, H1 2017 Melanoma - Pipeline by Idera Pharmaceuticals Inc, H1 2017 Melanoma - Pipeline by Ignyta Inc, H1 2017 Melanoma - Pipeline by Immodulon Therapeutics Ltd, H1 2017 Melanoma - Pipeline by Immune Design Corp, H1 2017 Melanoma - Pipeline by Immune Response BioPharma Inc, H1 2017 Melanoma - Pipeline by ImmunGene Inc, H1 2017 Melanoma - Pipeline by Immunocore Ltd, H1 2017 Melanoma - Pipeline by ImmunoGen Inc, H1 2017 Melanoma - Pipeline by Immupharma Plc, H1 2017 Melanoma - Pipeline by IMPACT Therapeutics Inc, H1 2017 Melanoma - Pipeline by Imugene Ltd, H1 2017 Melanoma - Pipeline by Incyte Corp, H1 2017 Melanoma - Pipeline by Infinity Pharmaceuticals Inc, H1 2017 Melanoma - Pipeline by Innovation Pharmaceuticals Inc, H1 2017 Melanoma - Pipeline by Inovio Pharmaceuticals Inc, H1 2017 Melanoma - Pipeline by InteRNA Technologies BV, H1 2017 Melanoma - Pipeline by Intezyne Technologies Inc, H1 2017 Melanoma - Pipeline by IO Biotech ApS, H1 2017 Melanoma - Pipeline by JHL Biotech Inc, H1 2017 Melanoma - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017 Melanoma - Pipeline by Johnson & Johnson, H1 2017 Melanoma - Pipeline by K-Stemcell Co Ltd, H1 2017 Melanoma - Pipeline by KaloBios Pharmaceuticals Inc, H1 2017 Melanoma - Pipeline by Kancera AB, H1 2017 Melanoma - Pipeline by Karyopharm Therapeutics Inc, H1 2017 Melanoma - Pipeline by Kite Pharma Inc, H1 2017 Melanoma - Pipeline by Leap Therapeutics Inc, H1 2017 Melanoma - Pipeline by Lentigen Technology Inc, H1 2017 Melanoma - Pipeline by Lindis Biotech GmbH, H1 2017 Melanoma - Pipeline by Lion Biotechnologies Inc, H1 2017 Melanoma - Pipeline by Lipotek Pty Ltd, H1 2017 Melanoma - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017 Melanoma - Pipeline by Loxo Oncology Inc, H1 2017 Melanoma - Pipeline by Lupin Ltd, H1 2017 Melanoma - Pipeline by Lytix Biopharma AS, H1 2017 Melanoma - Pipeline by MabVax Therapeutics Holdings Inc, H1 2017 Melanoma - Pipeline by MacroGenics Inc, H1 2017 Melanoma - Pipeline by Magnus Life Ltd, H1 2017 Melanoma - Pipeline by MaxiVAX SA, H1 2017 Melanoma - Pipeline by MediaPharma Srl, H1 2017 Melanoma - Pipeline by Medicenna Therapeutics Corp, H1 2017 Melanoma - Pipeline by MedImmune LLC, H1 2017 Melanoma - Pipeline by MELEMA Pharma GmbH, H1 2017 Melanoma - Pipeline by Merck & Co Inc, H1 2017 Melanoma - Pipeline by Merck KGaA, H1 2017 Melanoma - Pipeline by Millennium Pharmaceuticals Inc, H1 2017 Melanoma - Pipeline by Molecular Templates Inc, H1 2017 Melanoma - Pipeline by Moleculin Biotech Inc, H1 2017 Melanoma - Pipeline by Morphotek Inc, H1 2017 Melanoma - Pipeline by NantKwest Inc, H1 2017 Melanoma - Pipeline by Nektar Therapeutics, H1 2017 Melanoma - Pipeline by Neonc Technologies Inc, H1 2017 Melanoma - Pipeline by Nerviano Medical Sciences Srl, H1 2017 Melanoma - Pipeline by Neumedicines Inc, H1 2017 Melanoma - Pipeline by NewLink Genetics Corp, H1 2017 Melanoma - Pipeline by NormOxys Inc, H1 2017 Melanoma - Pipeline by Northwest Biotherapeutics Inc, H1 2017 Melanoma - Pipeline by Novartis AG, H1 2017 Melanoma - Pipeline by Novogen Ltd, H1 2017 Melanoma - Pipeline by Omeros Corp, H1 2017 Melanoma - Pipeline by Oncology Research International Ltd, H1 2017 Melanoma - Pipeline by Oncolys BioPharma Inc, H1 2017 Melanoma - Pipeline by Oncolytics Biotech Inc, H1 2017 Melanoma - Pipeline by OncoNOx ApS, H1 2017 Melanoma - Pipeline by OncoSec Medical Inc, H1 2017 Melanoma - Pipeline by OncoTartis Inc, H1 2017 Melanoma - Pipeline by Oncovir Inc, H1 2017 Melanoma - Pipeline by Onxeo SA, H1 2017 Melanoma - Pipeline by Opsona Therapeutics Ltd, H1 2017 Melanoma - Pipeline by Orega Biotech SAS, H1 2017 Melanoma - Pipeline by OSE Immunotherapeutics, H1 2017 Melanoma - Pipeline by Pacific Northwest Biotechnology LLC, H1 2017 Melanoma - Pipeline by Patrys Ltd, H1 2017 Melanoma - Pipeline by PepVax Inc, H1 2017 Melanoma - Pipeline by Peregrine Pharmaceuticals Inc, H1 2017 Melanoma - Pipeline by Pfizer Inc, H1 2017 Melanoma - Pipeline by Pharmicell Co Ltd, H1 2017 Melanoma - Pipeline by Pharminox Ltd, H1 2017 Melanoma - Pipeline by Pharmis Biofarmaceutica Lda, H1 2017 Melanoma - Pipeline by Philogen SpA, H1 2017 Melanoma - Pipeline by PinCell srl, H1 2017 Melanoma - Pipeline by Pivotal BioSciences Inc, H1 2017 Melanoma - Pipeline by Plexxikon Inc, H1 2017 Melanoma - Pipeline by Polaris Pharmaceuticals Inc, H1 2017 Melanoma - Pipeline by Polyplus-Transfection SA, H1 2017 Melanoma - Pipeline by Prima BioMed Ltd, H1 2017 Melanoma - Pipeline by Primevax Immuno Oncology Inc, H1 2017 Melanoma - Pipeline by Propanac Biopharma Inc, H1 2017 Melanoma - Pipeline by Provectus Biopharmaceuticals Inc, H1 2017 Melanoma - Pipeline by Provenance Biopharmaceuticals Corp, H1 2017 Melanoma - Pipeline by Qu Biologics Inc, H1 2017 Melanoma - Pipeline by Rafael Pharmaceuticals Inc, H1 2017 Melanoma - Pipeline by Reata Pharmaceuticals Inc, H1 2017 Melanoma - Pipeline by Recepta Biopharma SA, H1 2017 Melanoma - Pipeline by Recombio SL, H1 2017 Melanoma - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017 Melanoma - Pipeline by Rexahn Pharmaceuticals Inc, H1 2017 Melanoma - Pipeline by Rgenix Inc, H1 2017 Melanoma - Pipeline by Rubicon Biotechnology Inc, H1 2017 Melanoma - Pipeline by RXi Pharmaceuticals Corp, H1 2017 Melanoma - Pipeline by Sanofi, H1 2017 Melanoma - Pipeline by SATT North SAS, H1 2017 Melanoma - Pipeline by Scancell Holdings Plc, H1 2017 Melanoma - Pipeline by SilaGene Inc, H1 2017 Melanoma - Pipeline by Sillajen Biotherapeutics, H1 2017 Melanoma - Pipeline by SolaranRx Inc, H1 2017 Melanoma - Pipeline by Sorrento Therapeutics Inc, H1 2017 Melanoma - Pipeline by Spotlight Innovation Inc, H1 2017 Melanoma - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017 Melanoma - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017 Melanoma - Pipeline by Susavion Biosciences Inc, H1 2017 Melanoma - Pipeline by SuviCa Inc, H1 2017 Melanoma - Pipeline by Syndax Pharmaceuticals Inc, H1 2017 Melanoma - Pipeline by Synthon Holdings BV, H1 2017 Melanoma - Pipeline by Syntrix Biosystems Inc, H1 2017 Melanoma - Pipeline by Tactiva Therapeutics LLC, H1 2017 Melanoma - Pipeline by Taiga Biotechnologies Inc, H1 2017 Melanoma - Pipeline by Taiwan Liposome Company Ltd, H1 2017 Melanoma - Pipeline by Takara Bio Inc, H1 2017 Melanoma - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017 Melanoma - Pipeline by Takis Srl, H1 2017 Melanoma - Pipeline by Targovax ASA, H1 2017 Melanoma - Pipeline by TC BioPharm Ltd, H1 2017 Melanoma - Pipeline by Theravectys SA, H1 2017 Melanoma - Pipeline by Tikcro Technologies Ltd, H1 2017 Melanoma - Pipeline by TILT Biotherapeutics Ltd, H1 2017 Melanoma - Pipeline by Tiltan Pharma Ltd, H1 2017 Melanoma - Pipeline by Tocagen Inc, H1 2017 Melanoma - Pipeline by TREAT U SA, H1 2017 Melanoma - Pipeline by TVAX Biomedical Inc, H1 2017 Melanoma - Pipeline by UbiVac LLC, H1 2017 Melanoma - Pipeline by Ultimovacs AS, H1 2017 Melanoma - Pipeline by UNC Health Care, H1 2017 Melanoma - Pipeline by Vaccibody AS, H1 2017 Melanoma - Pipeline by Vascular Biogenics Ltd, H1 2017 Melanoma - Pipeline by Vault Pharma Inc, H1 2017 Melanoma - Pipeline by Vaxenta Biotechnologies, H1 2017 Melanoma - Pipeline by Vichem Chemie Research Ltd, H1 2017 Melanoma - Pipeline by ViiV Healthcare Ltd, H1 2017 Melanoma - Pipeline by Viralytics Ltd, H1 2017 Melanoma - Pipeline by ViraTherapeutics GmbH, H1 2017 Melanoma - Pipeline by VLP Therapeutics LLC, H1 2017 Melanoma - Pipeline by WntResearch AB, H1 2017 Melanoma - Pipeline by X4 Pharmaceuticals Inc, H1 2017 Melanoma - Pipeline by Zestagen SA, H1 2017 Melanoma - Dormant Projects, H1 2017 Melanoma - Dormant Projects, H1 2017 (Contd..1), H1 2017 Melanoma - Dormant Projects, H1 2017 (Contd..2), H1 2017 Melanoma - Dormant Projects, H1 2017 (Contd..3), H1 2017 Melanoma - Dormant Projects, H1 2017 (Contd..4), H1 2017 Melanoma - Dormant Projects, H1 2017 (Contd..5), H1 2017 Melanoma - Dormant Projects, H1 2017 (Contd..6), H1 2017 Melanoma - Dormant Projects, H1 2017 (Contd..7), H1 2017 Melanoma - Dormant Projects, H1 2017 (Contd..8), H1 2017 Melanoma - Dormant Projects, H1 2017 (Contd..9), H1 2017 Melanoma - Dormant Projects, H1 2017 (Contd..10), H1 2017 Melanoma - Dormant Projects, H1 2017 (Contd..11), H1 2017 Melanoma - Dormant Projects, H1 2017 (Contd..12), H1 2017 Melanoma - Dormant Projects, H1 2017 (Contd..13), H1 2017 Melanoma - Dormant Projects, H1 2017 (Contd..14), H1 2017 Melanoma - Dormant Projects, H1 2017 (Contd..15), H1 2017 Melanoma - Dormant Projects, H1 2017 (Contd..16), H1 2017 Melanoma - Dormant Projects, H1 2017 (Contd..17), H1 2017 Melanoma - Dormant Projects, H1 2017 (Contd..18), H1 2017 Melanoma - Dormant Projects, H1 2017 (Contd..19), H1 2017 Melanoma - Dormant Projects, H1 2017 (Contd..20), H1 2017 Melanoma - Dormant Projects, H1 2017 (Contd..21), H1 2017 Melanoma - Dormant Projects, H1 2017 (Contd..22), H1 2017 Melanoma - Dormant Projects, H1 2017 (Contd..23), H1 2017 Melanoma - Discontinued Products, H1 2017 Melanoma - Discontinued Products, H1 2017 (Contd..1), H1 2017 Melanoma - Discontinued Products, H1 2017 (Contd..2), H1 2017 Melanoma - Discontinued Products, H1 2017 (Contd..3), H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
